Snibe Diagnostic Presents Immunoassay Systems and Biochemistry Analyzers
|
By LabMedica International staff writers Posted on 02 Aug 2018 |

Image: The Biolumi 8000 integrated system (Photo courtesy of Snibe).
Snibe Diagnostic (ShenZhen, China), a leading provider of chemiluminescence immunoassay solutions, presented its range of instruments at the 70th AACC (Annual Scientific Meeting & Clinical Lab Expo), which took place in Chicago, Illinois, USA, from Jul. 29 to Aug. 2, 2018.
Snibe is a professional bio-medical company that specializes in the research, production and sale of clinical laboratory instruments and in vitro diagnostic reagents. It is the first Chinese company to receive FDA clearance for a chemiluminescence immunoassay product. The range of instruments presented by Snibe at this year’s AACC included the Biolumi 8000 integrated system, MAGLUMI 800 and MAGLUMI 2000 chemiluminiscence immunoassay systems and the Biossays 240 biochemistry analyzer.
The Biolumi 8000 integrated system combines an electrolyte module, chemistry module and immunoassay module in a single platform. Tests run on the system provide physicians with a wide range of assays, including 121 immunoassay, 47 chemistry, and four electrolyte assays. The Maglumi 800 chemiluminiscence immunoassay system features three modes of operation, sample loading for up to 40 sample tubes, continuous loading, STAT available, and LIS connection. The system offers a wide test menu, with a throughput of up to 180 tests per hour and the first results available in only 17 minutes. The MAGLUMI 2000 chemiluminiscence immunoassay system has a throughput of up to 180 tests/hour with time to first results of 17 minutes and is always ready-to-use. The Biossays 240 biochemistry analyzer has a throughput of constant 240 tests/hour and allows up to 90 sample positions to be loaded continuously on sample disk with barcode recognition.
Snibe is a professional bio-medical company that specializes in the research, production and sale of clinical laboratory instruments and in vitro diagnostic reagents. It is the first Chinese company to receive FDA clearance for a chemiluminescence immunoassay product. The range of instruments presented by Snibe at this year’s AACC included the Biolumi 8000 integrated system, MAGLUMI 800 and MAGLUMI 2000 chemiluminiscence immunoassay systems and the Biossays 240 biochemistry analyzer.
The Biolumi 8000 integrated system combines an electrolyte module, chemistry module and immunoassay module in a single platform. Tests run on the system provide physicians with a wide range of assays, including 121 immunoassay, 47 chemistry, and four electrolyte assays. The Maglumi 800 chemiluminiscence immunoassay system features three modes of operation, sample loading for up to 40 sample tubes, continuous loading, STAT available, and LIS connection. The system offers a wide test menu, with a throughput of up to 180 tests per hour and the first results available in only 17 minutes. The MAGLUMI 2000 chemiluminiscence immunoassay system has a throughput of up to 180 tests/hour with time to first results of 17 minutes and is always ready-to-use. The Biossays 240 biochemistry analyzer has a throughput of constant 240 tests/hour and allows up to 90 sample positions to be loaded continuously on sample disk with barcode recognition.
Latest AACC 2018 News
- Mesa Biotech Showcases PCR Testing Platform at Clinical Expo
- Mindray Medical Unveils Chemiluminescence Immunoassay System at AACC 2018
- Abbott Diagnostics Displays Alinity Family of Systems
- Roche Diagnostics Highlights Latest Clinical Lab Solutions at AACC
- Sysmex Highlights Innovations in Flow Cytometry, Urinalysis and Hematology
- Ortho Clinical Diagnostics Unveils Next-Gen Analyzer at Lab Show
- Thermo Fisher Scientific Showcases Product Portfolio at Lab Trade Show
- EKF Diagnostics Highlights Assay Kit and POC Analyzer at AACC 2018
- Randox Laboratories Showcases Advances in Biotechnology at Clinical Lab Expo
- Beckman Coulter Life Sciences Highlights Clinical Flow Cytometry Portfolio
- Beckman Coulter Features New Hematology Analyzers and Lab Automation
- Carolina Liquid Chemistries Promotes Family of Clinical Chemistry Analyzers
- Orion Diagnostica Showcases Rapid Test and Molecular Platform at Lab Show
- Saladax Biomedical Launches Game-Changing Assays at AACC 2018
- SeraCare Life Sciences Promotes New AccuSpan Panel at Lab Expo
- Sekisui Diagnostics Showcases Clinical Chemistry and Immunoassay Analyzers
Channels
Clinical Chemistry
view channel
First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more
Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options
Many lethal cancers lack routine screening and are often diagnosed only after symptoms emerge, limiting curative options. Standard programs in the United States cover a small subset of malignancies, leaving... Read more
Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes
Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors
Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read moreBlood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery
Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more
Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer
Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more
Electronic Genome Mapping Reveals Structural Abnormalities in Hematologic Malignancies
Cytogenomic profiling is fundamental to characterizing hematologic malignancies, where detection of structural variants and copy number variants guides high‑resolution analysis. Standard cytogenetic testing... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent
Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more
Blood Biomarker May Predict Colitis Risk in Checkpoint Inhibitor Therapy
Immune checkpoint inhibitors can trigger immune-related colitis that leads to severe diarrhea, abdominal pain, and treatment interruptions. Clinicians currently lack validated tools to identify which patients... Read more
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read moreMicrobiology
view channel
Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more
Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
Lyme disease and other tick-borne illnesses cause overlapping symptoms, making them difficult to distinguish clinically. The Centers for Disease Control and Prevention estimates that more than 476,000... Read morePathology
view channel
Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more
Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
Predicting which patients with early-stage breast cancer will develop distant recurrence remains difficult, complicating decisions about long-term therapy and surveillance. Widely used genomic assays are... Read more
Machine Learning Cytology Tool Improves Cancer Cell Identification
Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more
Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer
Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read moreTechnology
view channel
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing
Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals
Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read moreSputum-Based Lung Cancer Test Technology Granted Hong Kong Patent
Asia accounts for nearly two-thirds of lung cancer cases worldwide, with an estimated 1.6 million new diagnoses across the region each year. Against this substantial disease burden, a newly granted patent... Read more






.jpg)

